FDA Looking At Outside Research Alliances Through Advisory Committees
Executive Summary
FDA's Pharmaceutical Science/Nonclinical Studies Advisory Subcommittee is being watched as a model for using advisory committees to expand FDA's collaboration with outside sources.
You may also be interested in...
CDER Office of Testing & Research
Director James MacGregor, PhD, is leaving Center for Drug Evaluation & Research in January to join the National Center for Toxicological Research as deputy director-Washington operations. MacGregor has been on a four-month assignment as the CDER science leveraging coordinator (1"The Pink Sheet" Sept. 11, p. 24). OTR Acting Deputy Director Ajaz Hussain, PhD, has been serving as director of OTR
CDER Office of Testing & Research
Director James MacGregor, PhD, is leaving Center for Drug Evaluation & Research in January to join the National Center for Toxicological Research as deputy director-Washington operations. MacGregor has been on a four-month assignment as the CDER science leveraging coordinator (1"The Pink Sheet" Sept. 11, p. 24). OTR Acting Deputy Director Ajaz Hussain, PhD, has been serving as director of OTR
Cardiotoxicity, Vasculitis And PET Biomarker Groups To Be Formed By FDA
Vasculitis will be the focus of one of the three expert working groups endorsed by FDA's Advisory Committee for Pharmaceutical Science/Nonclinical Studies Subcommittee at its March 9 meeting.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: